V. Sondak

发表

Molecular classification of cutaneous malignant melanoma by gene expression profiling

N. Sampas, E. Dougherty, M. Bittner, 2000, Nature.

A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy

V. Sondak, R. P. Whitehead, J. Moon, 2004, Cancer.

Melanoma Prevention-Avoiding Indoor Tanning and Minimizing Overexposure to the Sun.

A. Halpern, V. Sondak, J. Gershenwald, 2016, JAMA.

Surgical therapy of primary cutaneous melanoma.

V. Sondak, T. Johnson, P. Geraghty, 1996, Seminars in surgical oncology.

The Unique Clinical Characteristics of Melanoma Diagnosed in Children

V. Sondak, J. Messina, J. Zager, 2012, Annals of Surgical Oncology.

Unanswered questions about margin recommendations for primary cutaneous melanoma.

V. Sondak, J. Wong, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy

V. Sondak, K. Tsai, E. Sokol, 2019, Clinical Cancer Research.

Final version of 2009 AJCC melanoma staging and classification.

Jeffrey E Gershenwald, Merrick I Ross, Charles M Balch, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Granulocyte‐macrophage–colony‐stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

V. Sondak, S. Groshen, J. Weber, 2003, Cancer.

Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role.

V. Sondak, A. Chang, A. Aruga, 1997, Journal of immunology.

Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I)

R. Elashoff, V. Sondak, A. Cochran, 2012, Annals of Surgical Oncology.

Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Jeffrey E Gershenwald, Lauren E Haydu, Merrick I Ross, 2017, CA: a cancer journal for clinicians.

Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee

V. Sondak, S. Broderick, G. Boland, 2020, Journal for ImmunoTherapy of Cancer.

Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512

V. Sondak, A. Ribas, J. Moon, 2012, PloS one.

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

V. Sondak, J. Sosman, J. Kirkwood, 2012, Clinical Cancer Research.

Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial

V. Sondak, J. Sosman, G. Weiss, 1999, Journal of Cancer Research and Clinical Oncology.

Response of extraabdominal desmoid tumors to therapy with imatinib mesylate

V. Sondak, Dafydd G. Thomas, C. Mcginn, 2002, Cancer.

Targeted therapies: Improved outcomes for patients with metastatic melanoma

V. Sondak, L. Flaherty, 2011, Nature Reviews Clinical Oncology.

Use of Anti-phosphohistone H3 Immunohistochemistry to Determine Mitotic Rate in Thin Melanoma

V. Sondak, J. Messina, L. F. Glass, 2010, The American Journal of dermatopathology.

Cutaneous melanoma: Role of lymphatic mapping and sentinel node biopsy

V. Sondak, A. Yahanda, L. Lowe, 2001 .

Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.

S. Merajver, K. Pienta, V. Sondak, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.

V. Sondak, K. Smalley, Ritin Sharma, 2016, Journal of proteome research.

Phase II Trial of Recombinant Human Interleukin‐4 in Patients with Disseminated Malignant Melanoma: A Southwest Oncology Group Study

V. Sondak, J. Unger, J. Thompson, 1998, Journal of immunotherapy.

Association between Human Polyomaviruses and Keratinocyte Carcinomas: A Prospective Cohort Study

V. Sondak, A. Giuliano, M. Schell, 2021, Cancer Epidemiology, Biomarkers & Prevention.

Cutaneous Human Papillomavirus Infection and Development of Subsequent Squamous Cell Carcinoma of the Skin

V. Sondak, J. Messina, M. Tommasino, 2016, Journal of skin cancer.

Merkel cell polyomavirus (MCV) T-antigen seroreactivity, MCV DNA in eyebrow hairs, and squamous cell carcinoma

V. Sondak, M. Pawlita, J. Messina, 2015, Infectious Agents and Cancer.

Genetic variations in the epidermodysplasia verruciformis (EVER/TMC) genes, cutaneous human papillomavirus infection and squamous cell carcinoma of the skin

V. Sondak, M. Schabath, M. Pawlita, 2015, The British journal of dermatology.

Case-control study of cutaneous human papillomavirus infection in Basal cell carcinoma of the skin.

V. Sondak, A. Giuliano, R. Roetzheim, 2013, The Journal of investigative dermatology.

Case–control Study of Merkel Cell Polyomavirus Infection and Cutaneous Squamous Cell Carcinoma

V. Sondak, A. Giuliano, R. Roetzheim, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Diagnostic procedures and pretreatment evaluation of soft tissue sarcomas.

V. Sondak, A. Chang, M. J. Arca, 1994, Seminars in surgical oncology.

Chemoprevention of melanoma: theoretical and practical considerations.

V. Sondak, M. Demierre, 2005, Cancer control : journal of the Moffitt Cancer Center.

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

V. Sondak, J. Kirkwood, T. Smith, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

V. Sondak, J. Sosman, J. Kirkwood, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative

V. Sondak, M. Atkins, B. Redman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current and planned multicenter trials for patients with primary or metastatic melanoma

V. Sondak, R. Kudchadkar, Dale Han, 2011, Journal of surgical oncology.

Adjuvant therapy for melanoma: a surgical perspective.

V. Sondak, R. Gonzalez, R. Kudchadkar, 2011, Surgical oncology clinics of North America.

Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma.

V. Sondak, R. Gonzalez, R. Kudchadkar, 2010, The Ochsner journal.

Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma.

A. Hauschild, D. Schadendorf, V. Sondak, 2010, European journal of cancer.

Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon

V. Sondak, U. Dafni, J. Kirkwood, 2010, Cancer.

Cytoreductive surgery for melanoma.

V. Sondak, J. Mcloughlin, J. Zager, 2007, Surgical oncology clinics of North America.

Current immunotherapy of melanoma

V. Sondak, M. Fishman, A. Daud, 2005 .

Melanoma: Adjuvant therapy and other treatment options

V. Sondak, M. Sabel, A. Terando, 2003, Current treatment options in oncology.

Use and abuse of statistics in evidence-based medicine.

V. Sondak, J. Kirkwood, M. Ernstoff, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How does interferon work? Does it even matter?

V. Sondak, 2002, Cancer.

Use of adjuvant therapy in cutaneous melanoma

V. Sondak, 2001, Expert review of anticancer therapy.

Early stage (I, II, III) melanoma

V. Sondak, M. Ross, L. Schuchter, 2001, Current treatment options in oncology.

Adjuvant therapy for melanoma.

V. Sondak, J. Wolfe, 1997, Current opinion in oncology.

A modified p53 overcomes mdm2-mediated oncogenic transformation: a potential cancer therapeutic agent.

V. Sondak, R. Reynolds, J. Lin, 2000, Cancer research.

A Modified p 53 Overcomes mdm 2-mediated Oncogenic Transformation : A Potential Cancer Therapeutic Agent 1

V. Sondak, Jiayuh Lin, R. Reynolds, 2000 .

Thin primary cutaneous melanomas

Jennifer L. Schwartz, V. Sondak, T. Hamilton, 2002, Cancer.

Preoperative Ultrasound is Not Useful for Identifying Nodal Metastasis in Melanoma Patients Undergoing Sentinel Node Biopsy: Preoperative Ultrasound in Clinically Node-Negative Melanoma

V. Sondak, M. Szabunio, Christy Y. Chai, 2012, Annals of Surgical Oncology.

Erratum to: What is the Significance of the In Transit or Interval Sentinel Node in Melanoma?

V. Sondak, J. Zager, C. Puleo, 2011, Annals of Surgical Oncology.

Desmoplastic Melanoma: Is There a Role for Sentinel Lymph Node Biopsy?

V. Sondak, Daohai Yu, J. Messina, 2013, Annals of Surgical Oncology.

Allogeneic and Autologous Melanoma Vaccines: Where Have We Been and Where Are We Going?

V. Sondak, M. Sabel, J. Mulé, 2006, Clinical Cancer Research.

The State of Melanoma: Emergent Challenges and Opportunities

V. Sondak, S. Swetter, A. Weeraratna, 2021, Clinical Cancer Research.

Is there a role for sentinel lymph node biopsy in the management of sarcoma?

V. Sondak, M. Sabel, D. Blazer, 2003, Surgical oncology.

Melanoma: MSLT-1—putting sentinel lymph node biopsy into context

V. Sondak, J. Zager, 2014, Nature Reviews Clinical Oncology.

The Challenge of Defining Guidelines for Sentinel Lymph Node Biopsy in Patients with Thin Primary Cutaneous Melanomas

V. Sondak, J. Gershenwald, D. Coit, 2012, Annals of Surgical Oncology.

Refining the criteria for sentinel lymph node biopsy in patients with thinner melanoma

V. Sondak, J. Messina, 2010, Cancer.

How Well Are We Taking Care of Melanoma Patients in the USA?

V. Sondak, 2008, Annals of Surgical Oncology.

Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials

Maria L. Wei, A. Marghoob, R. Dellavalle, 2018, Cancer.

Mitotic Rate and Younger Age Are Predictors of Sentinel Lymph Node Positivity: Lessons Learned From the Generation of a Probabilistic Model

Jeremy MG Taylor, V. Sondak, A. Chang, 2004, Annals of Surgical Oncology.

HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.

Yian A Chen, Dirk Schadendorf, John M Koomen, 2019, Cancer research.

Sentinel Lymph Node Biopsy Is Prognostic in Thickest Melanoma Cases and Should Be Performed for Thick Melanomas

V. Sondak, B. Pockaj, M. Kashani-Sabet, 2020, Annals of Surgical Oncology.

Resistance patterns to anti-PD-1 therapy in metastatic melanoma.

V. Sondak, J. Markowitz, A. Ozgun, 2016, Chinese clinical oncology.

Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation

R. Wilson, V. Sondak, L. Ding, 2016, Oncotarget.

Melanoma Genomics—Techniques and Implications for Therapy

V. Sondak, A. Weeraratna, A. Daud, 2008 .

Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma.

V. Sondak, Jong Y. Park, Ji‐Hyun Lee, 2013, Cancer epidemiology.

Immunostaining for cytokeratin 20 improves detection of micrometastatic Merkel cell carcinoma in sentinel lymph nodes.

V. Sondak, C. Bradford, L. Lowe, 2002, Journal of the American Academy of Dermatology.

Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy

Sephalie Y. Patel, James X. Sun, V. Sondak, 2019, World Journal of Surgery.

Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?

V. Sondak, K. Delman, J. Messina, 2020, Annals of Surgical Oncology.

Management of Locally and Regionally Recurrent Melanoma

V. Sondak, J. Zager, C. O’Donoghue, 2018 .

Selecting Patients With Thin Melanoma for Sentinel Lymph Node Biopsy-This Time It's Personal.

V. Sondak, J. Messina, J. Zager, 2017, JAMA dermatology.

A Collision of Diseases: Chronic Lymphocytic Leukemia Discovered During Lymph Node Biopsy for Melanoma

V. Sondak, J. Messina, J. Zager, 2013, Annals of Surgical Oncology.

Gene Variants in Angiogenesis and Lymphangiogenesis and Cutaneous Melanoma Progression

Jeffrey E. Lee, T. Sellers, V. Sondak, 2013, Cancer Epidemiology, Biomarkers & Prevention.

Surgically unresectable regional melanoma metastases in a patient with renal failure and peripheral vascular disease: are there safe and potentially effective treatments?

V. Sondak, H. Maguire, Takami Sato, 2010, Seminars in oncology.

Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?

V. Sondak, L. Flaherty, 2008, The Lancet.

Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.

V. Sondak, M. Buyse, R. Carlson, 1996, Journal of the National Cancer Institute.

The role of radiation therapy in the management of cutaneous melanoma.

V. Sondak, A. Trotti, N. Rao, 2011, Surgical oncology clinics of North America.

RE: A Comparison of Survival Rates for Treatment of Melanoma Metastatic to the Brain

V. Sondak, J. Douglas, 2004, Cancer investigation.

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee

B. Schilling, S. Puig, V. Sondak, 2020 .

Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base.

V. Sondak, B. Storer, J. Gershenwald, 2016, Journal of the National Cancer Institute.

Multimodality management of desmoid tumors: How important is a negative surgical margin?

V. Sondak, J. Zager, M. Melis, 2008, Journal of surgical oncology.

Questions in the Management of Stage I – III Merkel Cell Carcinoma

V. Sondak, J. Messina, L. F. Glass, 2014 .

Unanswered questions in the management of stage I-III Merkel cell carcinoma.

V. Sondak, J. Messina, L. F. Glass, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Malignant melanoma of the foot and ankle.

V. Sondak, T. Johnson, P. Fortin, 1995, The Journal of bone and joint surgery. American volume.

In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma.

V. Sondak, A. Silva, K. Smalley, 2013, Molecular pharmaceutics.

The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases e A multicenter cohort study

James X. Sun, V. Sondak, R. Dummer, 2022, European journal of cancer.

Leptomeningeal spread of breast cancer: Report of case and review of the literature

V. Sondak, P. Deckers, P. Mozden, 1981, Cancer.

Potential for Immunotherapy in Merkel Cell Carcinoma

V. Sondak, R. Deconti, K. McLean, 2010 .

Current Immunotherapy Practices in Melanoma.

V. Sondak, A. Sarnaik, N. Khushalani, 2019, Surgical oncology clinics of North America.

Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma

V. Sondak, G. Gibney, W. Janssen, 2012, Journal of immunotherapy.

Vaccine Therapy for Melanoma

V. Sondak, A. Sarnaik, N. Vohra, 2011 .

Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients.

V. Sondak, R. Gonzalez, M. Bui, 2012, International journal of radiation oncology, biology, physics.

Routine omission of sentinel lymph node biopsy for merkel cell carcinoma <= 1 cm is not justified.

V. Sondak, J. Messina, J. Zager, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?

V. Sondak, J. Torres-Roca, R. Gonzalez, 2018, Annals of Surgical Oncology.

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities

V. Sondak, M. Herlyn, M. Atkins, 2019, Pigment cell & melanoma research.

BRAF-MEK inhibition in melanoma brain metastases: a new hope.

V. Sondak, K. Smalley, P. Forsyth, 2017, The Lancet. Oncology.

Higher than reported adolescent and young adult clinical trial enrollment during the “Golden Age” of melanoma clinical trials

V. Sondak, D. Reed, N. Khushalani, 2018, Cancer medicine.

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

D. Schadendorf, V. Sondak, P. Ascierto, 2022, The Lancet.

Sentinel Lymph Node Biopsy in Melanoma and Other Cutaneous Malignancies | PER

V. Sondak, C. Ambe, 2014 .

Sentinel Lymph Node Biopsy in Melanoma and Other Cutaneous Malignancies

V. Sondak, C. Ambe, 2014 .

Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.

V. Sondak, Y. Shyr, B. Pockaj, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evidence-based clinical practice guidelines on the use of sentinel lymph node biopsy in melanoma.

V. Sondak, J. Gershenwald, S. Wong, 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Sentinel node biopsy and standard of care for melanoma.

V. Sondak, M. Ross, J. Gershenwald, 2009, Journal of the American Academy of Dermatology.

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males

V. Sondak, J. Kirkwood, F. Hodi, 2022, Journal of translational medicine.

Improved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck

V. Sondak, T. Strom, J. Torres-Roca, 2017, Head & neck.

Complete Spontaneous Regression of Pulmonary Metastatic Melanoma

V. Sondak, I. Francis, C. Slingluff, 1998, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Advances in melanoma therapy.

V. Sondak, A. Yahanda, T. Johnson, 1998, Journal of the American Academy of Dermatology.

Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.

V. Sondak, A. Chang, B. Fox, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma

V. Sondak, T. Padhya, M. Schell, 2015, Cancer.

Combined Analysis of Phase III Trials Evaluating [99mTc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma

V. Sondak, J. Messina, S. Leong, 2012, Annals of Surgical Oncology.

The Future of Melanoma Immunotherapy

V. Sondak, N. Khushalani, 2016 .

Expression of 12-lipoxygenase as a biomarker for melanoma carcinogenesis

V. Sondak, I. Shureiqi, D. Normolle, 2002, Melanoma research.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer

V. Sondak, E. Lipson, M. Tetzlaff, 2022, Journal for ImmunoTherapy of Cancer.

An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma

James X. Sun, V. Sondak, C. Slingluff, 2022, Annals of Surgical Oncology.

CNS metastases as a site of progression on SWOG intergroup study S0008: A phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 (BCT) versus high-dose interferon (HDI) in patients with high-risk melanoma.

V. Sondak, M. Atkins, J. Kirkwood, 2012 .

Desmoplastic and neurotropic melanoma

Jennifer L. Schwartz, V. Sondak, L. Lowe, 2004, Cancer.

Lymphatic mapping and sentinel lymph node biopsy in the detection of early metastasis from sweat gland carcinoma

V. Sondak, L. Lowe, D. Fullen, 2003, Cancer.

Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells

V. Sondak, D. Adeegbe, A. Sarnaik, 2022, Journal for ImmunoTherapy of Cancer.

Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies

V. Sondak, G. Gibney, J. Mulé, 2018, Cancer.

At the Confluence of Radiation Therapy and Immunotherapy: External Beam Radiation (EBRT) with Intratumoral Injection of Dendritic Cells as Neoadjuvant Treatment of High-risk Soft Tissue Sarcoma Patients

V. Sondak, M. Bui, R. Heysek, 2009 .

Computed tomography in staging of patients with melanoma metastatic to the regional nodes

V. Sondak, A. Chang, A. Yahanda, 1997, Annals of Surgical Oncology.

Activation of T lymphocytes for the adoptive immunotherapy of cancer

V. Sondak, A. Chang, J. Sussman, 1994, Annals of Surgical Oncology.

Lymphangiogenesis Induced by Surgery: A Risk for Melanoma Metastasis—Reply

V. Sondak, J. Messina, 2009 .

Allogeneic and AutologousMelanomaVaccines : Where HaveWe Been andWhereAreWeGoing ?

V. Sondak, M. Sabel, A. Mulè, 2006 .

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma

John E. Mullinax, V. Sondak, J. Mulé, 2018, Front. Oncol..

Adoptive cellular therapy of malignancy.

V. Sondak, J. Geiger, A. Chang, 1993, Archives of surgery.

Suppressive effects of visceral tumor on the generation of antitumor T cells for adoptive immunotherapy.

V. Sondak, A. Chang, P. Wagner, 1991, Archives of surgery.

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou

V. Sondak, M. Atkins, J. Sosman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues

V. Sondak, J. Weber, G. Phan, 2008, Annals of Surgical Oncology.

Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?

V. Sondak, J. Zager, 2009, Annals of Surgical Oncology.

Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.

V. Sondak, A. Chang, M. Cameron, 1993, Cancer research.

Extending the reach of BRAF-targeted cancer therapy

V. Sondak, G. Gibney, 2012, The Lancet.

Preoperative multimodality treatment of large soft tissue sarcomas. How can we get more (function) from less (surgery)?

V. Sondak, T. Lawrence, 1993, Cancer.

Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene.

V. Sondak, A. Chang, R. Mulligan, 1996, Human gene therapy.

The Florida Melanoma Trial I: A Prospective Multi-center Phase I/II Trial of Post-operative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-alpha in the Treatment of Advanced Stage III Melanoma

V. Sondak, C. Gwede, D. Reintgen, 2008 .

Soft tissue sarcomas of the extremity and retroperitoneum: advances in management.

V. Sondak, J. Economou, F. Eilber, 1991, Advances in surgery.

New Challenges in Endpoints for Drug Development in Advanced Melanoma

V. Sondak, K. Flaherty, J. Kirkwood, 2011, Clinical Cancer Research.

Single cell characterization of the cellular landscape of acral melanoma identifies novel targets for immunotherapy.

V. Sondak, F. Karreth, K. Smalley, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Interferon alfa-2a for melanoma metastases

V. Sondak, M. Ross, J. Kirkwood, 2002, The Lancet.

ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee.

B. Schilling, S. Puig, V. Sondak, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.

V. Sondak, J. Sosman, J. Kirkwood, 2017 .

Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

V. Sondak, J. Kirkwood, F. Hodi, 2022, Quality of Life Research.

Adjuvant immunotherapy for cancer: the next step.

V. Sondak, G. McArthur, 2015, The Lancet. Oncology.

Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study

V. Sondak, R. Scolyer, S. Lo, 2022, Annals of Surgical Oncology.

Pregnancy and the Use of Hormones in Melanoma Patients

V. Sondak, A. Gangi, R. Saw, 2020, Cutaneous Melanoma.

Case–control study of genus‐beta human papillomaviruses in plucked eyebrow hairs and cutaneous squamous cell carcinoma

V. Sondak, A. Giuliano, R. Roetzheim, 2014, International journal of cancer.

Age-Specific Seroprevalence of Merkel Cell Polyomavirus, BK Virus, and JC Virus

V. Sondak, A. Giuliano, J. Messina, 2011, Clinical and Vaccine Immunology.

ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee.

B. Schilling, S. Puig, V. Sondak, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee

B. Schilling, S. Puig, V. Sondak, 2020 .

United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.

V. Sondak, J. Sosman, J. Kirkwood, 2019, Journal of Clinical Oncology.

Adjuvant interferon: recommit or move on?

V. Sondak, R. Kudchadkar, 2011, The Lancet. Oncology.

Comparison of Single-Photon Emission Computed Tomography–Computed Tomography (SPECT/CT) and Conventional Planar Lymphoscintigraphy for Sentinel Node Localization in Patients with Cutaneous Malignancies

V. Sondak, J. Zager, N. Patel, 2017, Annals of Surgical Oncology.

Biopsy of the Sentinel Lymph Node

V. Sondak, A. Cochran, S. Wong, 2020, Cutaneous Melanoma.

Testing chemotherapeutic combinations in the human tumor colony—forming assay

V. Sondak, E. Korn, D. Morton, 1988 .

Evolution and clinical application of a rapid chemosensitivity assay

V. Sondak, D. Morton, D. Kern, 1985, Cancer.

Inhibition of BRAF and MEK in BRAF-mutant melanoma

V. Sondak, K. Smalley, 2015, The Lancet.

Cutaneous Angiosarcoma: A Single-Institution Experience

V. Sondak, T. Padhya, R. Gonzalez, 2013, Annals of Surgical Oncology.

Multidisciplinary management of special melanoma situations: Oligometastatic disease and bulky nodal sites

V. Sondak, J. Zager, A. Sarnaik, 2007, Current oncology reports.

A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin): A Southwest Oncology Group Study (S0331)

V. Sondak, M. Heinrich, J. Moon, 2010, American journal of clinical oncology.

CT of recurrent retroperitoneal sarcomas.

V. Sondak, I. Francis, R. Cohan, 2000, AJR. American journal of roentgenology.

Dermatofibrosarcoma Protuberans: How Wide Should We Resect?

V. Sondak, M. Bui, M. Sabel, 2010, Annals of Surgical Oncology.

Proper Margins of Excision in Dermatofibrosarcoma Protuberans: Wide or Narrow?

V. Sondak, M. Bui, J. Messina, 2008, Annals of Surgical Oncology.

Low recurrence rate after surgery for dermatofibrosarcoma protuberans

V. Sondak, L. Lowe, D. DuBay, 2004, Cancer.

Dermatofibrosarcoma protuberans: what is the best surgical approach?

V. Sondak, L. Lowe, D. DuBay, 1999, Surgical oncology.

Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread.

V. Sondak, N. Swanson, T. Hamilton, 1997, Journal of the American Academy of Dermatology.

Neoadjuvant Checkpoint Inhibitor Therapy for Merkel Cell Carcinoma.

V. Sondak, A. Brohl, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regression is significantly associated with outcomes for patients with melanoma.

V. Sondak, B. Pockaj, J. Messina, 2021, Surgery.

Current and future approaches in the surgical management of T3b/T4 primary and locoregionally advanced melanoma

V. Sondak, J. Messina, R. Neves, 2022, Cancer.

The Association of MUC16 Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma

V. Sondak, K. Tsai, M. Krauthammer, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

Richard Heller, V. Sondak, P. Munster, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.

V. Sondak, R. Gonzalez, E. Galanis, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pediatric melanoma: Analysis of an international registry

D. Jukic, V. Sondak, S. Swetter, 2013, Cancer.

Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group.

V. Sondak, K. Kopecky, P. Liu, 1994, Anti-cancer drugs.

A Phase II Trial of Interleukin‐2 and Interferon‐α in the Treatment of Metastatic Colorectal Carcinoma

V. Sondak, J. Geiger, D. V. Vander Woude, 1995 .

History of keratinocyte carcinoma and survival after a second primary malignancy: the Moffitt Cancer Center patient experience

V. Sondak, R. Amorrortu, Sandy Stewart, 2022, Journal of Cancer Research and Clinical Oncology.

Surgical management of melanoma

V. Sondak, E. Burke, 2018, Seminars in cutaneous medicine and surgery.

Age-Speciﬁc Seroprevalence of Merkel Cell Polyomavirus, BK Virus, and JC Virus (cid:1)

V. Sondak, A. Giuliano, J. Messina, 2011 .

Clinical application of the thymidine incorporation assay.

V. Sondak, D. Kern, S. Hildebrand-Zanki, 1987, Annals of clinical and laboratory science.

Growth inhibitory effect of sodium azide in chemosensitivity assays.

V. Sondak, D. Kern, S. Hildebrand-Zanki, 1987, International journal of cell cloning.

Analysis of the clinical utility of a predictive chemosensitivity assay.

V. Sondak, E. Korn, D. Kern, 1985, Statistics in medicine.

Effects of hormonal growth factors on colony formation and chemosensitivity of human tumors in agarose

V. Sondak, D. Kern, F. Chien, 1987, In Vitro Cellular & Developmental Biology.

Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.

V. Sondak, M. Atkins, B. Redman, 2012 .

99mTc-tilmanocept for lymphoscintigraphy

V. Sondak, C. Berman, J. Zager, 2013 .

Enhancing Effect of Interleukin 1α Administration on Antitumor Effector T-Cell Development

V. Sondak, A. Chang, M. Tuck, 1991 .

Prediction is Difficult, Especially About the Future: Clinical Prognostic Tools in Melanoma

V. Sondak, J. Messina, 2016, Annals of Surgical Oncology.

Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival

V. Sondak, B. Pockaj, J. Messina, 2019, Annals of Surgical Oncology.

Cutaneous Human Papillomaviruses and the Risk of Keratinocyte Carcinomas

V. Sondak, A. Giuliano, M. Schell, 2021, Cancer Research.

Merkel cell carcinoma and immunosuppression: what we still need to know.

V. Sondak, F. Locke, D. Rollison, 2015, Journal of the National Cancer Institute.

Cutaneous angiosarcoma of the scalp

V. Sondak, T. Pawlik, C. Mcginn, 2003, Cancer.

Completely regressed cutaneous melanocytic lesion revisited.

V. Sondak, J. Messina, T. McCardle, 2009, Seminars in oncology.

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508

V. Sondak, J. Sosman, J. Moon, 2010, Cancer.

Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study.

V. Sondak, S. Balcerzak, W. Samlowski, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study.

V. Sondak, D. Gandara, S. Balcerzak, 1999, The cancer journal from Scientific American.

Composite assessment of treatment response in patients (pts) with locally advanced basal cell carcinoma (laBCC): Sonidegib efficacy using two sets of response criteria.

V. Sondak, L. Schwartz, R. Dummer, 2015 .

Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials.

V. Sondak, J. Unger, L. Flaherty, 1998, American journal of clinical oncology.

Preoperative idoxuridine and radiation for large soft tissue sarcomas: Clinical results with five-year follow-up

V. Sondak, A. Chang, J. Robertson, 1998, Annals of Surgical Oncology.

Patterns of histologic response to neoadjuvant targeted therapy in patients with BRAF mutant melanoma.

V. Sondak, J. Messina, J. Markowitz, 2017 .

The Use of Omental Transposition in the Treatment of Recurrent Sarcoma of the Back

V. Sondak, D. Ladin, E. Wilkins, 1993, Annals of plastic surgery.

Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.

V. Sondak, M. Zalupski, L. Baker, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib.

V. Sondak, J. Messina, R. Kudchadkar, 2013, Journal of the American Academy of Dermatology.

Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients

V. Sondak, J. Messina, J. Zager, 2012, Journal of cutaneous pathology.

Shave biopsy is a safe and accurate method for the initial evaluation of melanoma.

V. Sondak, J. Messina, S. Hochwald, 2011, Journal of the American College of Surgeons.

Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma.

V. Sondak, B. Storer, J. Gershenwald, 2014, Journal of the American Academy of Dermatology.

The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma

V. Sondak, K. Griffith, A. Chang, 2007, Cancer.

Stratifying SLN incidence in intermediate thickness melanoma patients.

V. Sondak, B. Pockaj, J. Messina, 2017, American journal of surgery.

Nonsurgical Treatment Options for Basal Cell Carcinoma

V. Sondak, M. Lien, 2011, Journal of skin cancer.

Merkel cell carcinoma: pathologic findings and prognostic factors.

V. Sondak, J. Messina, J. Zager, 2010, Current problems in cancer.

The role of sentinel lymph node biopsy for melanoma: evidence assessment.

V. Sondak, M. Sabel, C. Bichakjian, 2006, Journal of the American Academy of Dermatology.

Surgical Management of Melanoma-In-Situ Using a Staged Marginal and Central Excision Technique

Graham S. Clark, V. Sondak, Daohai Yu, 2009, Annals of Surgical Oncology.

Standard immunostains for melanoma in sentinel lymph node specimens: which ones are most useful?

V. Sondak, T. Hamilton, L. Lowe, 2004, Journal of the American Academy of Dermatology.

Case–Control Study of Cutaneous Human Papillomaviruses in Squamous Cell Carcinoma of the Skin

V. Sondak, A. Giuliano, R. Roetzheim, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Sunlight exposure and cutaneous human papillomavirus seroreactivity in basal cell and squamous cell carcinomas of the skin.

V. Sondak, A. Giuliano, R. Roetzheim, 2012, The Journal of infectious diseases.

Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers

V. Sondak, A. Giuliano, M. Pawlita, 2008, International journal of cancer.

Cutaneous viral infections associated with ultraviolet radiation exposure

V. Sondak, A. Giuliano, M. Schell, 2020, International journal of cancer.

Case–control study of smoking and non-melanoma skin cancer

V. Sondak, A. Giuliano, J. Messina, 2012, Cancer Causes & Control.

Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system.

V. Sondak, M. Ross, B. Storer, 2010, Journal of the American Academy of Dermatology.

The surgical management of primary and metastatic Merkel cell carcinoma.

V. Sondak, T. Padhya, R. Gonzalez, 2010, Current problems in cancer.

Merkel Cell Carcinoma of Unknown Primary Origin

V. Sondak, R. Gonzalez, J. Messina, 2012, Annals of Surgical Oncology.

Surgical management of melanoma.

V. Sondak, G. Gibney, 2014, Hematology/oncology clinics of North America.

Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults.

V. Sondak, J. Messina, R. Kudchadkar, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Pediatric Melanoma and Atypical Melanocytic Neoplasms.

V. Sondak, J. Messina, D. Reed, 2016, Cancer treatment and research.

Management of familial melanoma and nonmelanoma skin cancer syndromes.

V. Sondak, L. F. Glass, A. Santillan, 2009, Surgical oncology clinics of North America.

State of the science 60th anniversary review

V. Sondak, M. Sabel, A. Daud, 2008, Cancer.

Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma

V. Sondak, T. Strom, J. Torres-Roca, 2016, Annals of Surgical Oncology.

Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions

V. Sondak, L. Lowe, T. Johnson, 2003, Cancer.

Integrating molecular biomarkers into current clinical management in melanoma.

V. Sondak, G. Gibney, R. Kudchadkar, 2014, Methods in molecular biology.

Metastatic nevoid melanoma in a 41/2‐year‐old child

V. Sondak, P. Duray, D. Cassarino, 2003, Journal of cutaneous pathology.

Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.

V. Sondak, M. Mihm, M. Ross, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma

J. Manola, J. Ibrahim, V. Sondak, 2004, Clinical Cancer Research.

Synthesis and characterization of a melanoma-targeted fluorescence imaging probe by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.

V. Sondak, Xuan Huang, D. Morse, 2012, Bioconjugate chemistry.

c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.

V. Sondak, K. Smalley, J. Weber, 2009, Histology and histopathology.

Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation.

Stephen M Hewitt, Kyle J Hewitt, V. Sondak, 2008, Cancer research.

The utility of fine needle aspiration in the diagnosis of melanoma metastatic to lymph nodes.

V. Sondak, A. Yahanda, T. Johnson, 1997, Journal of the American Academy of Dermatology.

Melanoma Vaccines

V. Sondak, M. Sabel, 2004 .

Malignant melanoma: current state of primary and adjuvant treatment.

V. Sondak, T. Pawlik, 2003, Critical reviews in oncology/hematology.

Tumor Vaccines

V. Sondak, M. Sabel, 2002, American journal of clinical dermatology.

Soft tissue sarcomas.

V. Sondak, D. Morton, J. Economou, 2004, Seminars in surgical oncology.

Modulation of Janus kinase 2 by cisplatin in cancer cells.

V. Sondak, Jiayuh Lin, D. Barber, 2004, International journal of oncology.

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.

V. Sondak, J. Sosman, J. Kirkwood, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Point: Interferon-α for Adjuvant Therapy for Melanoma Patients

V. Sondak, M. Sabel, 2004 .

Detection of Copy Number Alterations in Metastatic Melanoma by a DNA Fluorescence In situ Hybridization Probe Panel and Array Comparative Genomic Hybridization: A Southwest Oncology Group Study (S9431)

David D. Smith, V. Sondak, J. Sosman, 2008, Clinical Cancer Research.

Application of molecular cytogenetic techniques in a case study of human cutaneous metastatic melanoma.

P. Meltzer, V. Sondak, J. Trent, 2001, Cancer genetics and cytogenetics.

Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma.

V. Sondak, T. Strom, S. Eschrich, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

V. Sondak, R. Sullivan, M. Atkins, 2018, Journal of Immunotherapy for Cancer.

Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

V. Sondak, N. Tran, K. Smalley, 2021, Clinical Cancer Research.

The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020

V. Sondak, P. Ascierto, M. Atkins, 2021, Journal of translational medicine.

12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?

V. Sondak, S. Eschrich, M. Schell, 2012, Scientific Reports.

Beyond BRAF: where next for melanoma therapy?

V. Sondak, G. Gibney, K. Smalley, 2014, British Journal of Cancer.

Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.

V. Sondak, J. Sosman, 2003, Seminars in cancer biology.

Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma

V. Sondak, G. Gibney, K. Smalley, 2013, Nature Reviews Clinical Oncology.

Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma

V. Sondak, K. Smalley, J. Koomen, 2013, Molecular Cancer Therapeutics.

A brief history of melanoma: from mummies to mutations

V. Sondak, K. Smalley, V. Rebecca, 2012, Melanoma research.

Detection of Copy NumberAlterations in Metastatic Melanoma by a DNAFluorescence In situ Hybridization Probe Panel and Array Comparative Genomic Hybridization : A Southwest Oncology Group Study ( S 9431 )

David D. Smith, V. Sondak, J. Sosman, 2008 .

Clonal Architectures and Driver Mutations in Metastatic Melanomas

Li Ding, Malachi Griffith, Joshua F. McMichael, 2014, PloS one.

Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions.

V. Sondak, J. Messina, J. Zager, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

V. Sondak, K. Flaherty, K. Smalley, 2010, British Journal of Cancer.

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.

V. Sondak, K. Nathanson, A. Ribas, 2011, Cancer research.

Inhibition of autophagy enhances the effects of the AKT inhibitor MK‐2206 when combined with paclitaxel and carboplatin in BRAF wild‐type melanoma

V. Sondak, G. Gibney, K. Smalley, 2014, Pigment cell & melanoma research.

Progression of cutaneous melanoma: implications for treatment

A. Hauschild, V. Sondak, M. Mihm, 2012, Clinical & Experimental Metastasis.

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells

V. Sondak, K. Flaherty, J. Sosman, 2015, Oncogene.

Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough?

V. Sondak, R. Gonzalez, J. Messina, 2018, Annals of Surgical Oncology.

Cutaneous melanoma: pathogenesis and rationale for chemoprevention.

V. Sondak, M. Demierre, 2005, Critical reviews in oncology/hematology.

Is a Wider Margin (2 cm vs. 1 cm) for a 1.01–2.0 mm Melanoma Necessary?

V. Sondak, R. Gonzalez, J. Messina, 2016, Annals of Surgical Oncology.

A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin

V. Sondak, Jiayuh Lin, J. Lin, 2004, British Journal of Cancer.

Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience

V. Sondak, R. Gonzalez, M. Bui, 2015, PloS one.

The value of sentinel lymph node biopsy in the management of head and neck melanoma

V. Sondak, M. Alvarado, P.L. Stanley Leong, 2007, Journal of surgical oncology.

Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas.

V. Sondak, A. Chang, T. Lawrence, 1995, International journal of radiation oncology, biology, physics.

Title Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma : a Southwest Oncology Group study

V. Sondak, 2004 .

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.

V. Sondak, J. Doroshow, C. Taylor, 1995, Journal of the National Cancer Institute.

The future of targeted therapy approaches in melanoma

V. Sondak, K. Smalley, F. Meier, 2009, Expert opinion on drug discovery.

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.

Donna Niedzwiecki, Edward L Korn, Michael B Atkins, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

V. Sondak, M. Atkins, J. Sosman, 2013, Nature Reviews Clinical Oncology.

Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.

V. Sondak, A. Daud, D. Gabrilovich, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A centimeter here, a centimeter there: does it matter?

V. Sondak, T. Johnson, 1995, Journal of the American Academy of Dermatology.

Surgical therapy of cutaneous melanoma.

V. Sondak, M. Sabel, D. Blazer, 2007, Seminars in oncology.

Cutaneous melanoma: methods of biopsy and definitive surgical excision

V. Sondak, J. Messina, F. Glass, 2005, Dermatologic therapy.

Melanoma margins: the importance and need for more evidence-based trials.

V. Sondak, T. Johnson, 2004, Archives of dermatology.

Treatment of Head and Neck Melanoma In Situ With Staged Contoured Marginal Excisions

V. Sondak, J. Messina, J. Zager, 2017, Annals of plastic surgery.

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

V. Sondak, M. Ross, K. Shannon, 2022, Annals of Surgical Oncology.

Melanoma and Nonmelanoma Skin Cancer

Quan P. Ly, V. Sondak, Q. Ly, 2007 .

Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma.

Jennifer L. Schwartz, V. Sondak, B. Redman, 2004, Journal of the American Academy of Dermatology.

Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node‐negative melanoma

V. Sondak, J. Messina, K. Fisher, 2015, Cancer.

Melanoma Prognosis and Staging

V. Sondak, J. Kirkwood, R. Scolyer, 2019, Cutaneous Melanoma.

Clinicopathologic Predictors of Survival in Patients with Desmoplastic Melanoma

V. Sondak, J. Messina, J. Zager, 2015, PloS one.

Radiotherapy influences local control in patients with desmoplastic melanoma

V. Sondak, T. Strom, Daohai Yu, 2014, Cancer.

Markers and tissue resources for melanoma: meeting report.

V. Sondak, M. Mihm, S. Hewitt, 2006, Cancer research.

Melanoma and Other Cutaneous Malignancies

V. Sondak, K. Margolin, 2003 .

In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assay.

V. Sondak, E. Korn, D. Kern, 1988, International journal of cell cloning.

Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors.

V. Sondak, M. Kennedy, N. Tanigawa, 1985, Cancer research.

Liposarcoma of the spermatic cord: report of 6 cases and review of the literature.

V. Sondak, S. Schwartz, S. J. Swierzewski, 1995, The Journal of urology.

XL888 limits vemurafenib-induced proliferative skin events by suppressing paradoxical MAPK activation

V. Sondak, G. Gibney, K. Smalley, 2015, The Journal of investigative dermatology.

Melanoma in the brain: biology and therapeutic options

V. Sondak, G. Gibney, P. Forsyth, 2012, Melanoma research.

The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

V. Sondak, A. Ribas, K. Smalley, 2012, Clinical Cancer Research.

Systemic Therapy for Melanoma: ASCO Guideline.

V. Sondak, P. Ascierto, M. Atkins, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy for metastatic melanoma

V. Sondak, J. Kirkwood, H. Gogas, 2007, Cancer.

Unusual presentations of melanoma: melanoma of unknown primary site, melanoma arising in childhood, and melanoma arising in the eye and on mucosal surfaces.

V. Sondak, J. Messina, 2014, The Surgical clinics of North America.

Combination Therapies for Melanoma: A New Standard of Care?

V. Sondak, K. Smalley, Z. Eroglu, 2016, American Journal of Clinical Dermatology.

Treating melanoma in adolescents and young adults: challenges and solutions

V. Sondak, J. Messina, D. Reed, 2015 .

Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.

A. Hauschild, V. Sondak, P. Chapman, 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Novel treatments for melanoma brain metastases.

V. Sondak, N. Tran, G. Gibney, 2013, Cancer control : journal of the Moffitt Cancer Center.

Skin cancer: Targeted therapy for melanoma: is double hitting a home run?

V. Sondak, K. Smalley, 2013, Nature Reviews Clinical Oncology.

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

V. Sondak, M. Ross, M. Atkins, 2023, The New England journal of medicine.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

V. Sondak, J. Taube, M. Ross, 2019, The Lancet. Oncology.

Primary Tumor Thickness as a Prognostic Factor in Merkel Cell Carcinoma: The Next Big Thing?

V. Sondak, J. Messina, J. Zager, 2012, Annals of Surgical Oncology.

Merkel cell polyomavirus (MCV) T-antigen seroreactivity, MCV DNA in eyebrow hairs, and squamous cell carcinoma

V. Sondak, M. Pawlita, J. Messina, 2015, Infectious Agents and Cancer.

malignant melanoma by gene expression pro ®

N. Sampas, P. Meltzer, Y. Chen, 2022 .

Viruses in Skin Cancer (VIRUSCAN): Study Design and Baseline Characteristics of a Prospective Clinic-Based Cohort Study

V. Sondak, A. Giuliano, M. Pawlita, 2019, Cancer Epidemiology, Biomarkers & Prevention.

Staging workup, sentinel node biopsy, and follow-up tests for melanoma: update of current concepts.

Jennifer L. Schwartz, V. Sondak, S. Gruber, 2004, Archives of dermatology.

Regression in melanoma is significantly associated with a lower regional recurrence rate and better recurrence‐free survival

V. Sondak, B. Pockaj, J. Messina, 2021, Journal of surgical oncology.

Recent Advances in Melanoma Staging and Therapy

V. Sondak, M. Ross, K. McMasters, 1999, Annals of Surgical Oncology.

Sentinel lymph node biopsy in melanoma: Facts and controversies.

V. Sondak, N. Fenske, B. Cherpelis, 2010, Clinics in dermatology.

The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).

V. Sondak, M. Walker, L. Flaherty, 1996, American journal of clinical oncology.

Age as a Predictor of Sentinel Node Metastasis among Patients with Localized Melanoma: An Inverse Correlation of Melanoma Mortality and Incidence of Sentinel Node Metastasis Among Young and Old Patients

V. Sondak, M. Mihm, M. Ross, 2014, Annals of Surgical Oncology.

When will melanoma vaccines be proven effective?

V. Sondak, A. Weeraratna, J. Sosman, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

V. Sondak, J. Sosman, J. Unger, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma

Robert A. Gatenby, Y. Ann Chen, Inna Smalley, 2019, EBioMedicine.

Down-Regulation of Pro-Apoptotic Genes is an Early Event in the Progression of Malignant Melanoma

V. Sondak, J. Messina, A. Daud, 2007, Annals of Surgical Oncology.

Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations

V. Sondak, E. Korn, D. Kern, 1984, Cancer.

Where to start with systemic melanoma therapy?

V. Sondak, G. Gibney, K. Smalley, 2014, Melanoma management.

Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.

Maria L. Wei, Eric A. Smith, J. Stein, 2020, JAMA dermatology.

Lymphangiogenesis: host and tumor factors in nodal metastasis.

V. Sondak, J. Messina, 2008, Archives of dermatology.

Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma.

V. Sondak, J. Zager, C. Puleo, 2009, Cancer control : journal of the Moffitt Cancer Center.

Pros and cons of adjuvant interferon in the treatment of melanoma.

V. Sondak, M. Sabel, 2003, The oncologist.

Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.

V. Sondak, T. Karrison, D. Olson, 2020 .

Microsatellitosis in Patients with Melanoma

V. Sondak, P. Gimotty, B. Pockaj, 2018, Annals of Surgical Oncology.

Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).

V. Sondak, T. Karrison, D. Olson, 2018 .

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.

Jeffrey E Gershenwald, Merrick I Ross, Natale Cascinelli, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas.

V. Sondak, Audrey C Shor, S. Agresta, 2008, Cancer control : journal of the Moffitt Cancer Center.

Targeted therapy in melanoma.

V. Sondak, K. Smalley, L. F. Glass, 2013, Clinics in dermatology.

Sentinel node biopsy for thin melanomas: which patients should be considered?

V. Sondak, J. Messina, L. F. Glass, 2005, Cancer control : journal of the Moffitt Cancer Center.

Dermal melanoma: A report on prognosis, outcomes, and the utility of sentinel lymph node biopsy

V. Sondak, K. Egan, R. Gonzalez, 2016, Journal of surgical oncology.

A phase 2 trial of complete resection for stage IV melanoma

V. Sondak, B. Redman, J. Sosman, 2011, Cancer.

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

J. Utikal, D. Schadendorf, V. Sondak, 2017, European journal of cancer.

Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role?

V. Sondak, R. Kudchadkar, 2012, The oncologist.

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma

V. Sondak, A. Daud, A. Yver, 2010, Cancer Chemotherapy and Pharmacology.

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.

V. Sondak, B. Redman, J. Sosman, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma

V. Sondak, A. Daud, J. Weber, 2010, British Journal of Cancer.

Adjuvant Systemic Therapy for High-Risk Melanoma Patients

V. Sondak, Y. Najjar, J. Kirkwood, 2018, Cutaneous Melanoma.

Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma

V. Sondak, G. Gibney, K. Smalley, 2018, Clinical Cancer Research.

Improving patient outcomes to targeted therapies in melanoma

V. Sondak, K. Smalley, Z. Eroglu, 2016, Expert review of anticancer therapy.

BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy

V. Sondak, R. Gonzalez, G. Gibney, 2016, Melanoma research.

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

Kristina M. Ilieva, V. Petrenko, V. Sondak, 2014, Molecular Cancer Therapeutics.

Indications and options for systemic therapy in melanoma.

V. Sondak, G. Gibney, 2014, The Surgical clinics of North America.

Has targeted therapy for melanoma made chemotherapy obsolete?

V. Sondak, G. Gibney, 2013, The Lancet. Oncology.

Is the presence of tumor‐infiltrating lymphocytes predictive of outcomes in patients with melanoma?

V. Sondak, B. Pockaj, J. Messina, 2022, Cancer.

Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection

James X. Sun, V. Sondak, M. Schabath, 2021, Annals of Surgical Oncology.

Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2)

James X. Sun, Lesly A. Dossett, V. Sondak, 2021, Cancer.

Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era

James X. Sun, V. Sondak, Dennie T. Frederick, 2020, Annals of Surgical Oncology.

Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma.

V. Sondak, J. Messina, A. Tarhini, 2020, Journal of the American College of Surgeons.

Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience

V. Sondak, T. Strom, J. Torres-Roca, 2018, Melanoma management.

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

V. Sondak, M. Atkins, J. Sosman, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Minimizing Morbidity while Preserving Outcome after Inguinal Lymphadenectomy: Navigating between Scylla and Charybdis

V. Sondak, A. Sarnaik, 2011, Annals of Surgical Oncology.

Nonsentinel Node Metastases in Melanoma: Do They Reflect the Biology of the Tumor, the Lymph Node or the Surgeon?

V. Sondak, 2009, Annals of Surgical Oncology.

Treatment options for limited or symptomatic metastatic melanoma.

V. Sondak, J. Mcloughlin, L. Berk, 2008, Cancer Control: Journal of the Moffitt Cancer Cente.

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

V. Sondak, C. Chung, R. Slebos, 2022, The Lancet.

Sentinel Node Biopsy is Indicated for Thin Melanomas ≥0.76 mm

V. Sondak, Daohai Yu, R. Gonzalez, 2012, Annals of Surgical Oncology.

Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.

V. Sondak, R. Dunn, M. Zalupski, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High frequency of brain metastases after adjuvant therapy for high‐risk melanoma

V. Sondak, M. Atkins, J. Kirkwood, 2017, Cancer medicine.

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.

V. Sondak, J. Sosman, G. Weiss, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

V. Sondak, T. Karrison, D. Olson, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

D. Schadendorf, V. Sondak, P. Ascierto, 2021, Annals of Oncology.

Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival

V. Sondak, J. Sosman, A. Ribas, 2014, Cancer Immunology Research.

Melacine®: an allogeneic melanoma tumor cell lysate vaccine

V. Sondak, J. Sosman, 2003, Expert review of vaccines.

Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease

V. Sondak, R. Scolyer, I. Johansson, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up

V. Sondak, Daohai Yu, C. Gwede, 2012 .

Gender disparities in patients with melanoma: breaking the glass ceiling.

V. Sondak, S. Swetter, M. Berwick, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

V. Sondak, J. Sosman, J. Kirkwood, 2021, Journal for ImmunoTherapy of Cancer.

Melanoma Vaccines: Breakthrough or Bust?

V. Sondak, M. Sabel, 2002, Cancer investigation.

Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma.

Jennifer L. Schwartz, V. Sondak, K. Griffith, 2005, Journal of the American College of Surgeons.

Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials

V. Sondak, J. Unger, K. Albain, 2001 .

Surgical resection for stage IV melanoma: A Southwest Oncology Group trial (S9430).

V. Sondak, B. Redman, J. Sosman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit

V. Sondak, H. Hoekstra, B. Pockaj, 2019, Journal of surgical oncology.

How Do We Know When a Lymph Node Dissection is Adequate?

V. Sondak, 2011, Annals of Surgical Oncology.

Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay.

V. Sondak, E. Korn, D. Morton, 1984, Cancer research.

Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma

James X. Sun, V. Sondak, C. Slingluff, 2021, Annals of Surgical Oncology.

Sentinel lymph node biopsy for melanoma: indications and rationale.

V. Sondak, J. Messina, G. Phan, 2009, Cancer control : journal of the Moffitt Cancer Center.

Sentinel lymph node biopsy as the standard of care for cutaneous melanoma.

V. Sondak, J. Thomas, J. Messina, 2007, Clinical advances in hematology & oncology : H&O.

Is There a Role for Adjuvant High-Dose Interferon-α-2b in the Management of Melanoma?

V. Sondak, M. Sabel, 2012, Drugs.

Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease

R. Elashoff, V. Sondak, D. Elashoff, 2019, Annals of Surgical Oncology.

The prognostic significance of lymph node metastasis in pediatric melanoma and atypical melanocytic proliferations

V. Sondak, J. Messina, L. Turner, 2013 .

Current state of treatment for primary cutaneous melanoma

V. Sondak, M. Sabel, E. Chung, 2004, Clinical and Experimental Medicine.

Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary

V. Sondak, J. Kirkwood, P. Hwu, 2022, Journal for ImmunoTherapy of Cancer.

Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes

V. Sondak, R. Gonzalez, G. Gibney, 2016, The American surgeon.

Routine biopsy of cloquet's node is of limited value in sentinel node positive melanoma patients

V. Sondak, K. Delman, J. Messina, 2010, Journal of surgical oncology.

Treating Colon Cancer With a Melanoma Vaccine? Preposterous?

V. Sondak, A. Chang, 2001, Annals of Surgical Oncology.

Cutaneous leiomyosarcoma: treatment and outcomes with a standardized margin of resection.

V. Sondak, R. Gonzalez, M. Bui, 2013, Cancer control : journal of the Moffitt Cancer Center.

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines

V. Sondak, U. Rix, K. Smalley, 2017, Molecular Cancer Therapeutics.

Innovations and Challenges in Melanoma: Summary Statement from the First Cambridge Conference

M. Weinstock, V. Sondak, D. Elder, 2006, Clinical Cancer Research.

In vitro sensitivity of breast carcinoma to combination chemotherapy.

V. Sondak, A. Giuliano, D. Morton, 1984, Current surgery.

Genomic analysis of a case of agminated Spitz nevi and congenital‐pattern nevi arising in extensive nevus spilus

V. Sondak, J. Messina, J. Teer, 2018, Journal of cutaneous pathology.

Age as a Prognostic Factor in Patients with Localized Melanoma and Regional Metastases

V. Sondak, M. Mihm, M. Ross, 2013, Annals of Surgical Oncology.

Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model.

V. Sondak, J. Unger, L. Flaherty, 2002, American journal of clinical pathology.

An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma

James X. Sun, V. Sondak, C. Slingluff, 2022, Annals of Surgical Oncology.

Evaluation of Cisplatin and DTIC in Inoperable Stage III and IV Melanoma: A Southwest Oncology Group Study

V. Sondak, L. Hutchins, W. Fletcher, 1993, American journal of clinical oncology.

Single-institution Outcome Experience Using AlloDerm® as Temporary Coverage or Definitive Reconstruction for Cutaneous and Soft Tissue Malignancy Defects

V. Sondak, R. Gonzalez, J. Zager, 2013, The American surgeon.

Factors predicting survival in thick melanoma: Do all thick melanomas have the same prognosis?

V. Sondak, B. Pockaj, M. Kashani-Sabet, 2020, Surgery.

Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins

V. Sondak, R. Gonzalez, J. Messina, 2019, Melanoma management.

Behavior of Cutaneous Adnexal Malignancies: a Single Institution Experience

V. Sondak, J. Messina, B. Yue, 2018, Pathology & Oncology Research.

Full-Thickness Grafts Procured from Skin Overlying the Sentinel Lymph Node Basin; Reconstruction of Primary Cutaneous Malignancy Excision Defects

V. Sondak, Daohai Yu, D. Reintgen, 2008, Annals of Surgical Oncology.

The sentinel lymph node: More than just another blue lymph node

V. Sondak, J. Wagner, 2003, Cancer.

Management of intussusception in patients with melanoma

James X. Sun, V. Sondak, R. Gonzalez, 2019, Journal of surgical oncology.

Identifying risk factors using a skin cancer screening program.

V. Sondak, M. Schell, J. Messina, 2013, Cancer control : journal of the Moffitt Cancer Center.

What is the Significance of the In Transit or Interval Sentinel Node in Melanoma?

V. Sondak, J. Zager, C. Puleo, 2011, Annals of Surgical Oncology.

Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma.

V. Sondak, J. Unger, P Y Liu, 1997, American journal of clinical oncology.

What's new in pediatric melanoma and Spitz tumors? Pretty much everything

V. Sondak, J. Messina, 2021, Cancer.

Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.

V. Sondak, S. Brem, D. Reintgen, 2006, Cancer control : journal of the Moffitt Cancer Center.

Metastatic patterns of extremity liposarcoma and their outcome

V. Sondak, P. Pisters, 2002, Journal of surgical oncology.

Evaluation of interferon alpha‐2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026

V. Sondak, J. Moon, L. Hutchins, 2007, Cancer.

Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035

V. Sondak, J. Sosman, J. Unger, 2004 .

Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035.

V. Sondak, J. Sosman, J. Unger, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

V. Sondak, J. Kirkwood, F. Hodi, 2022, Quality of Life Research.

Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics*

V. Sondak, G. Gibney, K. Smalley, 2014, Molecular & Cellular Proteomics.

A phase II trial of piroxantrone in disseminated malignant melanoma

V. Sondak, J. Sosman, J. Thompson, 2007, Investigational New Drugs.

A phase II trial of interleukin-2 and interferon-alpha in the treatment of metastatic colorectal carcinoma.

V. Sondak, J. Geiger, D. V. Vander Woude, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter

V. Sondak, G. Gibney, K. Smalley, 2013, Clinical Cancer Research.

Meeting report: consensus from the first and second Global Workshops in Melanoma November 19–20, 2008

A. Hauschild, D. Schadendorf, A. Halpern, 2009, Pigment cell & melanoma research.

Melanoma--an unlikely poster child for personalized cancer therapy.

V. Sondak, K. Smalley, 2010, The New England journal of medicine.

Melanoma and human leukocyte antigen status: The missing link?

V. Sondak, A. Chang, 2002, Annals of Surgical Oncology.

Case–control study of smoking and non-melanoma skin cancer

V. Sondak, A. Giuliano, R. Roetzheim, 2012, Cancer Causes & Control.

Patterns and timing of sunlight exposure and risk of basal cell and squamous cell carcinomas of the skin – a case–control study

V. Sondak, A. Giuliano, R. Roetzheim, 2012, BMC Cancer.

Patterns and timing of sunlight exposure and risk of basal cell and squamous cell carcinomas of the skin – a case–control study

V. Sondak, A. Giuliano, R. Roetzheim, 2012, BMC Cancer.

Neural networks and artificial intelligence

Norman E. Sondak, Vernon K. Sondak, V. Sondak, 1989, SIGCSE '89.

Atypical Fibroxanthoma: Outcomes from a Large Single Institution Series

V. Sondak, J. Messina, J. Zager, 2023, Cancer Control: Journal of the Moffitt Cancer Cente.

Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy

Shannon C. Trotter, J. Stein, R. Dellavalle, 2017, Melanoma management.

Risk-stratified screening for detection of melanoma.

V. Sondak, A. Geller, L. F. Glass, 2015, JAMA.

Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing.

Maria L. Wei, Rajan P. Kulkarni, J. Stein, 2023, JAMA dermatology.

Procurement of Human Melanoma Specimens for Translational Research: Practical and Legal Considerations

V. Sondak, J. Messina, Shane A Huntsman, 2008 .

Targeting events in melanoma carcinogenesis for the prevention of melanoma

V. Sondak, M. Demierre, C. Lao, 2006, Expert review of anticancer therapy.

Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma.

V. Sondak, K. Griffith, James D. Murphy, 2007, International journal of radiation oncology, biology, physics.

Adenocarcinoma in a choledochal cyst during pregnancy: a case report and guidelines for management.

V. Sondak, J. Herd, J. Roslyn, 1988, Surgery.

Expression of receptor tyrosine kinases epidermal growth factor receptor and HER‐2/neu in synovial sarcoma

V. Sondak, T. Giordano, Dafydd G. Thomas, 2005, Cancer.

Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.

V. Sondak, J. Kirkwood, A. Ribas, 2022, JAMA oncology.

A Phase II Trial of Pyrazine Diazohydroxide in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – Southwest Oncology Group Study

V. Sondak, J. Unger, E. Kraut, 2002, Investigational New Drugs.

Tumor-induced suppression of antitumor reactivity and depression of TCRzeta expression in tumor-draining lymph node lymphocytes: possible relationship to the Th2 pathway.

V. Sondak, A. Chang, M. Cameron, 1997, Journal of immunotherapy.

Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review

V. Sondak, J. Kirkwood, A. Ribas, 2023, Cancers.

Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma.

V. Sondak, M. Knopp, J. Kirkwood, 2021, Cancer discovery.

Economic implications of hepatic arterial infusion versus intravenous chemotherapy or symptom palliation in the treatment of nonresectable colorectal liver metastases. Meta-Analysis Group In Cancer.

V. Sondak, M. Buyse, R. Carlson, 1999, Critical reviews in oncology/hematology.

Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer.

V. Sondak, M. Buyse, R. Carlson, 1997, Journal of the National Cancer Institute.

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma

V. Sondak, P. Munster, J. Messina, 2011, British Journal of Cancer.

Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.

V. Sondak, K. Flaherty, J. Kirkwood, 2015, Cancer discovery.

Phase II trial of sagopilone (ZK-EPO), a novel epothilone, in patients with metastatic melanoma

V. Sondak, A. Daud, J. Weber, 2008 .

Robotic-Assisted Transperitoneal Pelvic Lymphadenectomy for Metastatic Melanoma: Early Outcomes Compared with Open Pelvic Lymphadenectomy.

Lesly A. Dossett, V. Sondak, J. Pow-Sang, 2016, Journal of the American College of Surgeons.

Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ [TT]), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508

V. Sondak, J. Sosman, J. Moon, 2008 .

Chemical Therapeutics Inhibition of Wee 1 , AKT , and CDK 4 Underlies the Ef fi cacy of the HSP 90 Inhibitor XL 888 in an In Vivo Model of NRAS-Mutant Melanoma

V. Sondak, K. Smalley, J. Koomen, 2013 .

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants, and association with outcome: E1609 study analysis.

V. Sondak, J. Kirkwood, F. Hodi, 2020 .

Vitamin D and Melanoma: What Do We Tell Our Patients?

V. Sondak, P. Kanetsky, B. Mciver, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Staged margin control techniques for surgical excision of lentigo maligna.

Graham S. Clark, V. Sondak, L. F. Glass, 2009, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933

V. Sondak, B. Redman, A. Ribas, 2015, Cancer.

International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers

James X. Sun, Lesly A. Dossett, V. Sondak, 2022, Annals of surgery.

Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: Survival analysis of 6,908 cases from the National Cancer Data Base.

V. Sondak, B. Storer, J. Gershenwald, 2014 .

Progression of cutaneous melanoma: implications for treatment

A. Hauschild, V. Sondak, M. Mihm, 2012, Clinical & Experimental Metastasis.

Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer

F. Marincola, V. Sondak, E. Jaffee, 2011, Journal of Translational Medicine.

Expression of CXCR4, E-Cadherin, Bcl-2, and Survivin in Merkel Cell Carcinoma: An Immunohistochemical Study Using a Tissue Microarray

V. Sondak, M. Schell, J. Messina, 2012, The American Journal of dermatopathology.

V. Sondak, D. August, T. Rea, 2006, Annals of Surgical Oncology.

Neoadjuvant BRAF‐targeted therapy in regionally advanced and oligometastatic melanoma

V. Sondak, J. Messina, J. Markowitz, 2020, Pigment cell & melanoma research.

Retroperitoneal sarcomas

V. Sondak, I. Francis, R. Cohan, 2005, Cancer imaging : the official publication of the International Cancer Imaging Society.

Sentinel Lymph Node Biopsy in Patients with T1a Cutaneous Malignant Melanoma: A Multi-Center Cohort Study.

V. Sondak, A. Sinnamon, J. Zager, 2022, Journal of the American Academy of Dermatology.

Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial.

V. Sondak, S. Balcerzak, L. Flaherty, 1992, Journal of the National Cancer Institute.

A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study.

V. Sondak, J. Sosman, J. Thompson, 1995, Investigational new drugs.

Expanded access programmes: patient interests versus clinical trial integrity.

A. Hauschild, D. Schadendorf, V. Sondak, 2015, The Lancet. Oncology.

History of keratinocyte carcinoma and survival after a second primary malignancy: the Moffitt Cancer Center patient experience

V. Sondak, R. Amorrortu, Sandy Stewart, 2022, Journal of Cancer Research and Clinical Oncology.

Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report

V. Sondak, K. Smalley, 2009, Pigment Cell & Melanoma Research.

Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.

V. Sondak, C. Mcginn, F. Worden, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multi-institutional melanoma vaccine trial

V. Sondak, 1996, Annals of Surgical Oncology.

Phase II Trial of CI-980 in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – A Southwest Oncology Group Study

V. Sondak, J. Unger, W. Samlowski, 2004, Investigational New Drugs.

SWOG S1404: A phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma.

V. Sondak, J. Kirkwood, A. Ribas, 2016 .

SWOG S0826: A phase II trial of SCH 727965 (NSC 747135) in patients with stage IV melanoma.

V. Sondak, A. Ribas, J. Moon, 2012 .

Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma

V. Sondak, E. Kraut, M. Slavik, 2004, Investigational New Drugs.

Targeted therapy in melanoma.

V. Sondak, H. Tawbi, K. Smalley, 2013, Clinics in dermatology.

Abstract 2491: Quantification of biomarker expression, phosphorylation, and mutation in cancer using TMT labeling prior to liquid chromatography-multiple reaction monitoring mass spectrometry

V. Sondak, K. Smalley, A. Magliocco, 2014 .

New directions for medical artificial intelligence

Vernon K. Sondak, N. E. Sondak, V. Sondak, 1990 .

Liposarcoma of the spermatic cord: report of 6 cases and review of the literature.

V. Sondak, H. Grossman, S. Schwartz, 1995, The Journal of urology.

Staging and prognostic factors for stage IV melanoma: Initial results of an American Joint Committee on Cancer (AJCC) international evidence-based assessment of 4,895 melanoma patients

V. Sondak, J. Kirkwood, A. Eggermont, 2008 .

Current status of biomarkers for melanoma metastasis.

V. Sondak, J. Messina, 2006, IDrugs : the investigational drugs journal.

Testing chemotherapeutic combinations in the human tumor colony—forming assay

V. Sondak, E. Korn, D. Morton, 1988, Journal of Surgical Oncology.

Relationships between primary tumor size , number of involved nodes and survival among 8 , 044 cases of Merkel cell carcinoma

V. Sondak, A. Sober, D. Byrd, 2019 .

Echoes of a failure: what lessons can we learn?

V. Sondak, N. Khushalani, 2019, The Lancet Oncology.

Systemic Therapy for Melanoma: ASCO Guideline Update

V. Sondak, P. Ascierto, M. Atkins, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acral melanoma: clinical advances and hope for the future.

V. Sondak, J. Messina, R. Neves, 2023, Clinical advances in hematology & oncology : H&O.

Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy

V. Sondak, J. Unger, W. Samlowski, 2001 .

Adjuvant and Neoadjuvant Therapy in High-Risk Stage III Cutaneous Melanoma.

V. Sondak, N. Khushalani, 2017, International Journal of Radiation Oncology, Biology, Physics.

Setting the bar for adjuvant treatment of melanoma.

V. Sondak, G. Gibney, 2014, The Lancet Oncology.

340 POSTER Gene therapy with plasmid IL-12 delivered by electroporation in patients with malignant melanoma: results of first human Phase I trial

V. Sondak, J. Messina, A. Daud, 2006 .

Combined BRAF, MEK, and heat‐shock protein 90 inhibition in advanced BRAF V600‐mutant melanoma

V. Sondak, K. Smalley, A. Brohl, 2023, Cancer.

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

V. Sondak, J. Sosman, J. Kirkwood, 2012, Clinical Cancer Research.

In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma.

V. Sondak, A. Silva, K. Smalley, 2013, Molecular Pharmaceutics.

Case–control Study of Merkel Cell Polyomavirus Infection and Cutaneous Squamous Cell Carcinoma

V. Sondak, A. Giuliano, R. Roetzheim, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

V. Sondak, P. Munster, D. Sullivan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.

V. Sondak, A. Daud, D. Gabrilovich, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Rapidly Changing Landscape of Advanced-Stage Melanoma Treatment and Its Implications for New Drug Development

V. Sondak, H. Gogas, Mark R. Middleton, 2012 .

Multimodality management of desmoid tumors: How important is a negative surgical margin?

V. Sondak, J. Zager, M. Melis, 2008, Journal of surgical oncology.

Phase II trial of sagopilone (ZK-EPO), a novel synthetic epothilone, with significant activity in metastatic melanoma.

V. Sondak, A. Daud, J. Weber, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system.

V. Sondak, M. Ross, B. Storer, 2010, Journal of the American Academy of Dermatology.

Natural history of incident and persistent cutaneous human papillomavirus and human polyomavirus infections.

V. Sondak, A. Giuliano, T. Waterboer, 2022, Journal of Infectious Diseases.

Melanoma and CLL co-occurrence and survival: role of KC history

V. Sondak, J. Pinilla-Ibarz, R. Amorrortu, 2023, BMC Cancer.

Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients

V. Sondak, J. Wargo, R. Amaria, 2018, Cutaneous Melanoma.

Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients

V. Sondak, J. Wargo, R. Amaria, 2020, Cutaneous Melanoma.

Abstract 5370: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

V. Sondak, K. Smalley, J. Messina, 2011 .

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

V. Sondak, K. Smalley, N. Wallis, 2014, Molecular Cancer Therapeutics.

Expression of receptor tyrosine kinases epidermal growth factor receptor and HER‐2/neu in synovial sarcoma

V. Sondak, T. Giordano, Dafydd G. Thomas, 2005, Cancer.

Reproducibility of lymphoscintigraphic drainage patterns in sequential 99mTc human serum albumin and 99mTc sulfur colloid studies: implications for sentinel node identification in melanoma.

V. Sondak, R. Wahl, A. Yahanda, 1999, Surgery.

Microsatellitosis in Patients with Melanoma

V. Sondak, P. Gimotty, B. Pockaj, 2018, Annals of Surgical Oncology.

The Challenge of Defining Guidelines for Sentinel Lymph Node Biopsy in Patients with Thin Primary Cutaneous Melanomas

V. Sondak, J. Gershenwald, D. Coit, 2012, Annals of Surgical Oncology.

Lymphangiogenesis: host and tumor factors in nodal metastasis.

V. Sondak, J. Messina, 2008, Archives of dermatology.

Unusual presentations of melanoma: melanoma of unknown primary site, melanoma arising in childhood, and melanoma arising in the eye and on mucosal surfaces.

V. Sondak, J. Messina, 2014, The Surgical clinics of North America.

Radar-Guided Localization and Resection for Metastatic Nodal and Soft Tissue Melanoma: A Single-Institution Retrospective Study

V. Sondak, J. Zager, A. Sarnaik, 2024, Cancer control : journal of the Moffitt Cancer Center.

4 Bone Sarcoma ... Turning the Corner

Shawna V. Hudson, V. Sondak, G. Bepler, 2008 .

Abstract 809: BRAF wild-type melanoma survival hinges upon AKT activity and adaptive autophagic reprogramming in response to chemotherapy

V. Sondak, G. Gibney, K. Smalley, 2014 .

Clonal architectures and driver mutations in metastatic Clonal architectures and driver mutations in metastatic melanomas melanomas

Joshua F. McMichael, O. Griffith, V. Sondak, 2022 .

Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation.

V. Sondak, E. Bernstein, Dan Hasson, 2024, JCI insight.